CD70 UCAR T cells Therapy (Nanjing Calmhome Cell and Gene Engineering Institute)

N/A

Report date: 2026/04/24 20:01:59

Base Information

Drug NameCD70 UCAR T cells Therapy (Nanjing Calmhome Cell and Gene Engineering Institute)
Drug Alias NameCHT101CHT-101
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD70T lymphocyte replacements
TargetsCD70 antigen
Therapy Area/IndicationsSolid tumoursLupus Erythematosus, SystemicNeoplasm Metastasis +[13
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsSolid tumoursLupus Erythematosus, SystemicNeoplasm Metastasis +[13
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A